Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Butyrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Butyrate SCHEMBL4695 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14339600 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL21111521 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14473210 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL11209085 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL14936050 | 1.00 | NR3C2 (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Butyrate SCHEMBL8397588 | 0.98 | NR3C2 (0.97) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Valerate SCHEMBL11356233 | 0.98 | HIF1A (0.97) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Valerate SCHEMBL80603 | 0.96 | HIF1A (1.00) | NR3C2PGRNR3C1HIF1AKMT2A | |
| Hydrocortisone Valerate SCHEMBL21111527 | 0.96 | HIF1A (1.00) | NR3C2PGRNR3C1HIF1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2021 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144059-A1 | GUANIDINOACETIC ACID, ITS DERIVATES, COMPOSITIONS AND METHODS OF USE THEREOF | YU RUEY J (US) | 2025-05-08 | — | — | US | claimed |
| US-20250002591-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHERMATOSUS PATIENTS | ASTRAZENECA AB (SE) | 2025-01-02 | — | — | US | claimed |
| EP-4442241-A2 | RETINOL REPLACEMENT IN SKIN TREATMENT | Symrise AG (DE) | 2024-10-09 | — | — | EP | claimed |
| EP-4412641-A2 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | claimed |
| EP-3773445-B1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2024-07-24 | — | — | EP | claimed |
| EP-4377349-A1 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-06-05 | — | — | EP | claimed |
| CN-118076379-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-4337696-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS | Astrazeneca AB (SE) | 2024-03-20 | — | — | EP | claimed |
| CN-117677638-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-03-08 | — | — | CN | claimed |
| EP-4326322-A1 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS | Astrazeneca AB (SE) | 2024-02-28 | — | — | EP | claimed |
| EP-0223671-B1 | MEDICAMENT WITH A SYNERGISTIC ANTI-INFLAMMATORY EFFECT ON THE BASIS OF A CORTICOSTEROID AND A BETA-AGONIST | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1991-11-27 | — | — | EP | claimed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| EP-0036138-B2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1989-10-25 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| US-4367224-A | ANTIINFLAMMATORY AGENTS, SKIN DISORDERS | SCOTT EUGENE J VAN | 1983-01-04 | — | — | US | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4221787-A | Esteramide prodrugs of anti-inflammatory corticosteroids | INTERX RESEARCH CORPORATION (US) | 1980-09-09 | — | — | US | claimed |